CVRx Gestione
Criteri Gestione verificati 3/4
CVRx Il CEO è Kevin Hykes, nominato in Feb2024, e ha un mandato di 2.25 anni. la retribuzione annua totale è $ 3.91M, composta da 16.9% di stipendio e 83.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.19% delle azioni della società, per un valore di $ 316.11K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2 anni e 4.8 anni.
Informazioni chiave
Kevin Hykes
Amministratore delegato
US$3.9m
Compenso totale
| Percentuale dello stipendio del CEO | 16.91% |
| Mandato del CEO | 2.3yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 2yrs |
| Durata media del Consiglio di amministrazione | 4.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Articolo di analisi • May 15
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 22% to US$5.74 in the week since its...
Aggiornamento della narrazione • May 05
CVRX: Reduced Multiple Expectations Will Likely Constrain Future Share Price Upside
Analysts have reduced their average CVRx price target by $1 to reflect updated views on the company’s risk profile, growth trajectory, profitability expectations, and likely P/E multiple, while keeping fair value broadly in line with prior estimates. Analyst Commentary Recent Street research on CVRx points to a more cautious tone, with the headline takeaways centered on slightly lower price targets and an increased focus on execution and valuation risks.Aggiornamento della narrazione • Apr 19
CVRX: Execution Risks And Updated Assumptions Will Likely Restrain Upside
Analysts have trimmed their price targets on CVRx by $1, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research notes, including one from JPMorgan, point to a more cautious stance on CVRx, reflected in the $1 price target trims.Aggiornamento della narrazione • Mar 31
CVRX: Execution Risks And Recent Price Cuts Will Likely Limit Upside
Analysts have trimmed their CVRx price targets by $1 to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations, while maintaining their fair value estimate at $6.00. Analyst Commentary Recent Street research, including updated work from JPMorgan, reflects a more cautious stance on CVRx even as the published fair value estimate remains at $6.00.Aggiornamento della narrazione • Mar 16
CVRX: Execution Risks Around Profitability Path Will Likely Cap Future Upside
Analysts have trimmed their CVRx price targets by $1 to $6, reflecting updated assumptions around revenue growth, discount rate, profit margins, and future P/E expectations. Analyst Commentary Recent research updates point to a more cautious stance on CVRx, with both JPMorgan and other bearish analysts trimming price targets by $1.Aggiornamento della narrazione • Mar 01
CVRX: Reimbursement Progress Will Face Cautious Outlook On Profitability Path
Analysts have trimmed their price target on CVRx by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins and forward P/E that still align with recent Street research from firms that reduced their targets by a similar amount. Analyst Commentary Street research on CVRx has recently centered on slightly lower price targets, including a US$1 trim from JPMorgan, which aligns with similar reductions from other bearish analysts.Articolo di analisi • Feb 15
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
One of the biggest stories of last week was how CVRx, Inc. ( NASDAQ:CVRX ) shares plunged 24% in the week since its...Aggiornamento della narrazione • Feb 15
CVRX: Reimbursement Shift And BENEFIT-HF Trial Will Reshape Long-Term Upside
Analysts have trimmed their CVRx price targets by $1, reflecting updated fair value estimates and assumptions on growth, profitability, and future P/E multiples, while maintaining a constructive view on the story. Analyst Commentary Recent Street research includes price target trims of $1 from both JPMorgan and other bearish analysts, which reflect a more cautious stance on CVRx's risk and reward profile.Articolo di analisi • Dec 30
CVRx, Inc.'s (NASDAQ:CVRX) Popularity With Investors Under Threat As Stock Sinks 26%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • Nov 08
CVRx, Inc. (NASDAQ:CVRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.50
CVRx, Inc. ( NASDAQ:CVRX ) just released its quarterly report and things are looking bullish. CVRx beat expectations...Articolo di analisi • Oct 16
After Leaping 39% CVRx, Inc. (NASDAQ:CVRX) Shares Are Not Flying Under The Radar
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a really impressive month, gaining 39% after a shaky period beforehand...Articolo di analisi • Sep 16
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Aug 08
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Second-Quarter Report
It's been a sad week for CVRx, Inc. ( NASDAQ:CVRX ), who've watched their investment drop 13% to US$6.94 in the week...Articolo di analisi • Jul 15
CVRx, Inc.'s (NASDAQ:CVRX) P/S Is Still On The Mark Following 25% Share Price Bounce
CVRx, Inc. ( NASDAQ:CVRX ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jul 02
CVRx: Sell-Off Ignores Its True Potential
Summary CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up. Management insider buying and a net cash balance sheet reinforce my conviction that CVRX is a speculative Buy at these levels. Read the full article on Seeking AlphaArticolo di analisi • Jun 14
Is CVRx (NASDAQ:CVRX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • May 09
Investors Appear Satisfied With CVRx, Inc.'s (NASDAQ:CVRX) Prospects As Shares Rocket 25%
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 25% in the last...Seeking Alpha • Apr 09
CVRx, Inc.: Overreaction Creates Buying Opportunity
Summary CVRx, Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness. CVRX shares are a buy with a price target of $10. Read the full article on Seeking Alpha
Nuova narrazione • Mar 29
Expanding 48 US Territories And New Codes Will Broaden Access
Expansion in US territories and implanting centers is expected to drive significant revenue growth and market penetration.Articolo di analisi • Mar 07
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a horrible month, losing 29% after a relatively good period beforehand...Articolo di analisi • Jan 16
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 27%
Despite an already strong run, CVRx, Inc. ( NASDAQ:CVRX ) shares have been powering on, with a gain of 27% in the last...Articolo di analisi • Dec 26
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Nov 07
CVRx: Impressive Top-Line Growth Seems Priced In
Summary CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. CVRX is a hold with a price target of $14. Read the full article on Seeking AlphaArticolo di analisi • Nov 01
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report
The investors in CVRx, Inc. 's ( NASDAQ:CVRX ) will be rubbing their hands together with glee today, after the share...Articolo di analisi • Oct 10
Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)
When you see that almost half of the companies in the Medical Equipment industry in the United States have...Articolo di analisi • Jul 31
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Jun 18
Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 32% in the last...Articolo di analisi • May 04
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%
To the annoyance of some shareholders, CVRx, Inc. ( NASDAQ:CVRX ) shares are down a considerable 47% in the last month...Articolo di analisi • Apr 10
Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Feb 29
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • Nov 11
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders are no doubt pleased to see that the share price has bounced 34% in the last...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$53m |
| Dec 31 2025 | US$4m | US$661k | -US$53m |
| Sep 30 2025 | n/a | n/a | -US$52m |
| Jun 30 2025 | n/a | n/a | -US$52m |
| Mar 31 2025 | n/a | n/a | -US$52m |
| Dec 31 2024 | US$9m | US$570k | -US$60m |
| Sep 30 2024 | n/a | n/a | -US$58m |
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$52m |
| Dec 31 2023 | US$137k | n/a | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$43m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$43m |
| Dec 31 2022 | US$246k | n/a | -US$41m |
Compensazione vs Mercato: La retribuzione totale di Kevin ($USD 3.91M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.66M ).
Compensazione vs guadagni: La retribuzione di Kevin è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Kevin Hykes (59 yo)
2.3yrs
Mandato
US$3,905,801
Compensazione
Mr. Kevin Hykes serves as Director of CVRx, Inc. since December 21, 2022 and serves as President and Chief Executive Officer since February 12, 2024. He served as President, Director & Chief Executive Offi...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.3yrs | US$3.91m | 0.19% $ 316.1k | |
| Chief Medical Officer | 2yrs | US$1.36m | 0.021% $ 34.1k | |
| Chief Revenue Officer | 1.9yrs | US$1.76m | 0.037% $ 59.8k | |
| Chief Financial Officer | 5.6yrs | US$1.57m | 0.072% $ 117.3k | |
| Chief Operating Officer | less than a year | Nessun dato | Nessun dato | |
| Chief Marketing & Strategy Officer | 5.3yrs | US$1.08m | 0.013% $ 21.7k | |
| Chief Human Resources Officer | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Patient Access | 2yrs | Nessun dato | Nessun dato |
2.0yrs
Durata media
59yo
Età media
Gestione esperta: Il team dirigenziale di CVRX è considerato esperto (durata media dell'incarico 2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 3.4yrs | US$3.91m | 0.19% $ 316.1k | |
| Independent Director | 1.7yrs | US$167.99k | Nessun dato | |
| Independent Lead Director | 17.6yrs | US$210.49k | 0.12% $ 187.2k | |
| Independent Director | 5.8yrs | US$168.99k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$170.49k | 0.021% $ 34.5k | |
| Independent Director | 1.7yrs | US$156.62k | Nessun dato | |
| Independent Director | 4.8yrs | US$158.37k | 0% $ 0 |
4.8yrs
Durata media
59.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CVRX sono considerati esperti (durata media dell'incarico 4.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/25 17:13 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
CVRx, Inc. è coperta da 9 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Sarah James | Cantor Fitzgerald & Co. |